Abstract
Amongst ionotropic glutamatergic receptors, the AMPA receptor subtype has been recognized as a major contributor to the fast excitatory neurotransmission in the central nervous system and the expression and maintenance of longterm potentiation. This receptor subtype also represents an interesting target to develop innovative therapeutic drugs such as positive allosteric modulators (AMPA receptor potentiators) since the enhancement of AMPA signals is expected to be beneficial in the management of several neurological disorders such as depression, schizophrenia, Parkinsons disease and learning-memory deficits linked to Alzheimers disease. This article is dedicated to the use of (hetero)aromatic ring-fused thiadiazines (i.e. benzo- pyrido- and thienothiadiazines) as core structures for the discovery of new positive allosteric modulators of AMPA receptors. Recent advances exploring other chemotypes in the field of AMPA potentiators is the object of a separate review of the present issue.
Keywords: Positive allosteric modulators, AMPA receptor potentiators, benzothiadiazines, pyridothiadiazines, thienothiadiazines, neurological disorders, ionotropic glutamatergic receptors, Alzheimer's disease, schizophrenia, Parkinson's disease, postsynaptic receptors, modulators, thienothiadiazi-nes, central nervous system, Kainic acid
Current Medicinal Chemistry
Title: Ring-Fused Thiadiazines as Core Structures for the Development of Potent AMPA Receptor Potentiators
Volume: 17 Issue: 30
Author(s): B. Pirotte, P. Francotte, E. Goffin, P. Fraikin, L. Danober, B. Lesur, I. Botez, D.-H. Caignard, P. Lestage and P. de Tullio
Affiliation:
Keywords: Positive allosteric modulators, AMPA receptor potentiators, benzothiadiazines, pyridothiadiazines, thienothiadiazines, neurological disorders, ionotropic glutamatergic receptors, Alzheimer's disease, schizophrenia, Parkinson's disease, postsynaptic receptors, modulators, thienothiadiazi-nes, central nervous system, Kainic acid
Abstract: Amongst ionotropic glutamatergic receptors, the AMPA receptor subtype has been recognized as a major contributor to the fast excitatory neurotransmission in the central nervous system and the expression and maintenance of longterm potentiation. This receptor subtype also represents an interesting target to develop innovative therapeutic drugs such as positive allosteric modulators (AMPA receptor potentiators) since the enhancement of AMPA signals is expected to be beneficial in the management of several neurological disorders such as depression, schizophrenia, Parkinsons disease and learning-memory deficits linked to Alzheimers disease. This article is dedicated to the use of (hetero)aromatic ring-fused thiadiazines (i.e. benzo- pyrido- and thienothiadiazines) as core structures for the discovery of new positive allosteric modulators of AMPA receptors. Recent advances exploring other chemotypes in the field of AMPA potentiators is the object of a separate review of the present issue.
Export Options
About this article
Cite this article as:
Pirotte B., Francotte P., Goffin E., Fraikin P., Danober L., Lesur B., Botez I., Caignard D.-H., Lestage P. and de Tullio P., Ring-Fused Thiadiazines as Core Structures for the Development of Potent AMPA Receptor Potentiators, Current Medicinal Chemistry 2010; 17 (30) . https://dx.doi.org/10.2174/092986710792927859
DOI https://dx.doi.org/10.2174/092986710792927859 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Prion Diseases: Targets and Treatments of Symptoms and Disease Progression (Guest Editor: Brian Appleby)]
CNS & Neurological Disorders - Drug Targets Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction
Current Pharmaceutical Design Molecular Mechanisms of PPAR-γ Governing MSC Osteogenic and Adipogenic Differentiation
Current Stem Cell Research & Therapy Obsessive-Compulsive Disorder with Suicide Obsessions Triggered by News Reports about the “Blue Whale Game”
Adolescent Psychiatry Neuropathic Pain: Is the End of Suffering Starting in the Gene Therapy?
Current Drug Targets Reversal of Tumor Induced Dendritic Cell Paralysis: A Treatment Regimen Against Cancer
Current Immunology Reviews (Discontinued) Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs
Current Drug Metabolism Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Results of Group Psychotherapy for Abuse, Neglect and Pregnancy Loss
Current Women`s Health Reviews Advances in Cognitive-Behavioral Therapy for Youth with Anxiety Disorders: A Brief Summary
Current Psychiatry Reviews The Pharmacology of Human Appetite Expression
Current Drug Targets Opiate-Induced Analgesia: Contributions From Mu, Delta and Kappa Opioid Receptors Mouse Mutants
Current Pharmaceutical Design Inflammatory and Cell Death Pathways in Brain and Peripheral Blood in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Knowing When to Trust Your Gut: The Intimate Relationship Between Neurodegenerative Diseases and the Brain-Gut Axis
Current Neurovascular Research Electrochemical Biosensors for the Determination of the Antioxidant Capacity in Foods and Beverages Based on Reactive Oxygen Species
Current Analytical Chemistry Editorial [Hot Topic: Novel Therapeutic Strategies in Neural Diseases Uncover Unexpected Disease Connections: From Neurodegeneration and Addiction to Pain and Depression (Guest Editor: Gonzalo Herradon)]
Current Pharmaceutical Design Cannabinoids and Psychosis
Current Pharmaceutical Design Genetics of Ion Channels in Sudden Unexplained Death Syndrome: Moving Beyond Idiopathic Reactions To Personalized Risk Assessment
Current Pharmacogenomics and Personalized Medicine New Insights in Research About Acute Ischemic Myocardial Injury and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets